Comparative Pharmacology
Head-to-head clinical analysis: ELIXOMIN versus PHYLLOCONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXOMIN versus PHYLLOCONTIN.
ELIXOMIN vs PHYLLOCONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Sustained-release theophylline; nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase activator. Bronchodilation via relaxation of bronchial smooth muscle; also reduces airway hyperresponsiveness and inflammation.
500 mg orally once daily with a full glass of water, regardless of meals.
For chronic obstructive pulmonary disease and asthma: initial dose 225 mg orally twice daily; may increase to 450 mg twice daily. Based on theophylline, target serum concentration 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life: 3-8 hours in non-smoking adults; reduced to 1.5-5 hours in smokers; prolonged to 10-30 hours in heart failure or hepatic cirrhosis.
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of clearance; metabolites eliminated renally.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator